Patents Assigned to Synergen, Inc.
-
Patent number: 8006740Abstract: A method of forming a brake rotor includes forming a plurality of metal insert portions. Each insert portion includes an inner side and an outer side with a plurality of attachment members coupled to the inner side. The method also includes positioning the plurality of insert portions into a mold such that the inner side of one of the plurality of insert portions faces the inner side of another one of the insert portions. The method also includes introducing a molten aluminum into the mold such that the molten aluminum contacts the inner side of each insert portion. The method further includes forming a mechanical bond between the aluminum and at least a portion of at least one of the inserts.Type: GrantFiled: October 8, 2008Date of Patent: August 30, 2011Assignee: Synergen, IncInventor: Peter Strom
-
Patent number: 5459048Abstract: A class of polypeptides useful in an in vitro diagnosis of Mycoplasma infection in animals is disclosed. These polypeptides are also capable of inducing an immune response in swine which were previously not exposed to Mycoplasma. Recombinant DNA methods for the production of these polypeptides and certain phage vectors and DNA sequences useful in these methods are also disclosed. Methods of vaccinating animals utilizing a vaccination composition which includes these polypeptides is also disclosed.Type: GrantFiled: November 17, 1993Date of Patent: October 17, 1995Assignee: Synergen, Inc.Inventors: Jerry Kuner, Christine Ko
-
Patent number: 5453490Abstract: A method for the production of commercial quantities of highly purified interleukin-1 inhibitor (IL-1i) from a recombinant host is disclosed. A preferred recombinant E. coli host for use in this method is also disclosed.Type: GrantFiled: August 30, 1994Date of Patent: September 26, 1995Assignee: Synergen, Inc.Inventors: Robert Hageman, Stephen P. Eisenberg, David Dripps, Ronald Evans, Henryk Cudny, Robert C. Thompson
-
Patent number: 5332804Abstract: High molecular weight forms of therapeutic proteins are disclosed which are single-polypeptide-chain proteins that contain the same or similar therapeutic activity as the therapeutic protein. In particular, high molecular weight forms of the human bFGF angiogenic factor are disclosed which are single-polypeptide-chain proteins having at least one active site possessing an activity selected from the group consisting of mitogenic activity, chemotactic activity, angiogenic activity, neurotrophic activity, the ability to stimulate protease synthesis and combinations thereof. The high molecular weight angiogenic factors exhibit substantial homology to and are immunologically equivalent to the native high molecular weight forms isolatable from human hepatoma cells. The high molecular weight angiogenic factors are produced by DNA translation initiating at non-ATG codons and incorporate additional polypeptide sequences N-terminal to the human bFGF factor.Type: GrantFiled: April 16, 1991Date of Patent: July 26, 1994Assignee: Synergen, Inc.Inventors: Robert Z. Florkiewicz, Andreas Sommer
-
Patent number: 5235043Abstract: This invention describes processes for producing mature human members of the NGF/BDNF family of neurotrophic proteins that are fully biologically active. In addition, the gene encoding human BDNF and processes for obtaining the same are disclosed.A previously-unreported member of the NGF/BDNF family of neurotrophic proteins, NGF-3, has been identified and a portion of the gene encoding for the NGF-3 has been described. Processes for identifying additional previously unreported members of the NGF/BDNF family are also described.Type: GrantFiled: October 9, 1990Date of Patent: August 10, 1993Assignee: Synergen, Inc.Inventors: Frank Collins, Susan Bektesh, Tadahiko Kohno, Jack Lile
-
Patent number: 5188943Abstract: High molecular weight forms of therapeutic proteins are disclosed which are single-polypeptide-chain proteins that contain the same or similar therapeutic activity as the therapeutic protein. In particular, high molecular weight forms of the human bFGF angiogenic factor are disclosed which are single-polypeptide-chain proteins having at least one active site possessing an activity selected from the group consisting of mitogenic activity, chemotactic activity, angiogenic activity, neurotrophic, activity, the ability to stimulate protease synthesis and combinations thereof. The high molecular weight angiogenic factors exhibit substantial homology to and are immunologically equivalent to the native high molecular weight forms isolatable from human hepatoma cells. The high molecular weight angiogenic factors are produced by DNA translation initiating at non-ATG codons and incorporate additional polypeptide sequences N-terminal to the human bFGF factor.Type: GrantFiled: April 17, 1991Date of Patent: February 23, 1993Assignee: Synergen, Inc.Inventors: Robert Z. Florkiewicz, Andreas Sommer
-
Patent number: 5141856Abstract: A ciliary neurotrophic factor (CNTF), particularly sciatic nerve CNTF (SN-CNTF) is claimed. The SN-CNTF described herein is a single protein species and has a specific activity that increased to greater than 25,000-fold from crude extract.Amino acid data for this SN-CNTF is also provided. In addition, methods for using this data for providing SN-CNTF probes and for screening cDNA and genomic libraries are also provided. Recombinant-DNA methods for the production of SN-CNTF are described.Nucleic acid sequences encoding rabbit and human CNTF are provided. A recombinant expression system is provided for producing biologically active CNTF.Type: GrantFiled: December 28, 1989Date of Patent: August 25, 1992Assignee: Synergen, Inc.Inventors: Franklin D. Collins, Leu-Fen Lin, Drzislav Mismer, Christine Ko
-
Patent number: 5075222Abstract: DNA sequences that encode Interleukin-1 inhibitors and recombinant-DNA methods for the production of interleukin-1 inhibitors are provided. The DNA sequences encode proteins having interleukin-1 inhibitors activity.Type: GrantFiled: April 6, 1990Date of Patent: December 24, 1991Assignee: Synergen, Inc.Inventors: Charles H. Hannum, Stephen P. Eisenburg, Robert C. Thompson, William P. Arend, Fenneke G. Joslin
-
Patent number: 5026839Abstract: An isolated DNA sequence encoding an angiogenic factor protein consisting of a single-polypeptide-chain protein having at least one active site possessing mitotic and chemotactic activity and the ability to stimulate protease synthesis, wherein said protein consists of the amino acid sequence: ##STR1## In a preferred embodiment, the DNA sequence encodes basic fibroblast growth factor (bFGF).Type: GrantFiled: April 5, 1990Date of Patent: June 25, 1991Assignees: Synergen, Inc, New York UniversityInventors: David A. Moscatelli, Daniel B. Rifkin, Andreas Sommer
-
Patent number: 4997929Abstract: A ciliary neurotrophic factor (CNTF), particularly sciatic nerve CNTF(SN-CNFT) is claimed. The SN-CNTF described herein is a single protein species and has a specific activity that increased to greater than 25,000-fold from crude extract.Amino acid data for this SN-CNTF is also provided. In addition, methods for using this data for providing SN-CNTF probes and for screening cDNA and genomic libraries are also provided. Recombinant-DNA methods for the production of SN-CNTF are described.Nucleic acid sequences encoding rabbit and human CNTF are provided. A recombinant expression system is provided for producing biologically active CNTF.Type: GrantFiled: September 8, 1989Date of Patent: March 5, 1991Assignee: Synergen, Inc.Inventors: Franklin D. Collins, Leu-Fen Lin
-
Patent number: 4994559Abstract: An angiogenic factor is disclosed which is a purified, single-polypeptide-chain protein having at least one active site possessing an activity selected from the group consisting of mitogenic activity, chemotactic activity, the ability to stimulate protease synthesis and combinations thereof. This angiogenic factor exhibits substantial homology to and is immunologically equivalent to the native angiogenic factor isolatable from human placental tissues. The amino acid sequence of this angiogenic factor is also disclosed. In addition, a method for isolation of the purified angiogenic factor from human placental tissues is set forth. Pharmaceutical preparations incorporating this angiogenic factor are described.Type: GrantFiled: January 26, 1989Date of Patent: February 19, 1991Assignees: Synergen, Inc., New York UniversityInventors: David A. Moscatelli, Daniel B. Rifkin, Andreas Sommer